A Study of Language Interpretation Solutions for People With Breast Cancer

Conditions

• Breast Cancer
• Breast Cancer Stage II
• Breast Cancer Stage III

Eligibility Criteria

Sex

ALL

Age

18 Years - N/A

Healthy Volunteers

Not accepted

Interventions

• Remote Simultaneous Medical Interpreting/RSMI — OTHER
  Remote Simultaneous Medical Interpreting (RSMI), "UN-style" simultaneous interpreting applied to the medical encounter, which holds tremendous promise for closely approximating a same language encounter, decreasing interpreting errors, and improving outcomes.
• Remote Consecutive Medical Interpreting/RCMI — OTHER
  Remote Consecutive Medical Interpreting (RCMI; "audio consecutive"), is the most commonly utilized remote interpreting
• Remote Consecutive Video Medical Interpreting/RCVI — OTHER
  Remote Simultaneous Medical Interpreting (RSMI), "UN-style" simultaneous interpreting applied to the medical encounter

Study Details

The study will be conducted in 2 overlapping phases. In Phase 1, there will be a 3-arm randomized controlled trial of Remote Simultaneous Medical Interpreting/RSMI (Arm 1), versus Remote Consecutive Medical Interpreting/RCMI (Arm 2) and versus Remote Consecutive Video Medical Interpreting/RCVI (Arm 3) in breast cancer outpatient clinical encounters with Spanish- and Mandarin-speaking patients with Limited English Proficiency/LEP (Stages II and III disease) and English- speaking providers (who do not speak Spanish/Mandarin). In Phase 2, there will be a sequential mixed-methods explanatory, multi-stakeholder process evaluation to gather implementation potential data.

Key Dates

Start date

Dec 2, 2024

Status verified

May 2026

Primary completion

Dec 2, 2029

Completion

Dec 2, 2029

Study Design

Enrollment

700 participants (estimated)

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

HEALTH_SERVICES_RESEARCH

Arms

• Experimental: Phase I: Remote Simultaneous Medical Interpreting/RSMI (Arm 1)
  This phase will enroll Spanish- and Mandarin-speaking patients with LEP (Stages II and III disease) and English- speaking providers
• Experimental: Phase I: Remote Consecutive Medical Interpreting/RCMI (Arm 2)
  This phase will enroll Spanish- and Mandarin-speaking patients with LEP (Stages II and III disease) and English- speaking providers
• Experimental: Phase I: Remote Consecutive Video Medical Interpreting/RCVI (Arm 3)
  This phase will enroll Spanish- and Mandarin-speaking patients with LEP (Stages II and III disease) and English- speaking providers
• Experimental: Phase II: CFIR mixed-methods explanatory, multi- stakeholder process evaluation
  Will examine RSMI utilization (Arm 1 participants only and clinic staff), intervention barriers and facilitators, and implementation potential

Primary Outcome Measure

Number of interpretation errors [ Time Frame: up to 30 days ]

Central Contacts

• Francesca Gany, MD, MS
  646-888-8054
  [email protected]
• Lisa Diamond, MD
  646-888-8061
  [email protected]

Locations (8)

Find similar trials in Basking Ridge, NJ

Related Studies

• Serum Biomarkers to Characterize the Effects of Therapy on Ovarian Reserve in Premenopausal Women With Early-stage Breast Cancer or BRCA Mutations
  Recruiting · Memorial Sloan Kettering Cancer Center · Basking Ridge, New Jersey
• I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer
  PHASE2 · Recruiting · QuantumLeap Healthcare Collaborative · Birmingham, Alabama
• Phase II Protocol of Proton Therapy for Partial Breast Irradiation in Early Stage Breast Cancer
  PHASE2 · Recruiting · Proton Collaborative Group · Scottsdale, Arizona
• Longitudinal Sexual and Reproductive Health Study of Women With Breast Cancer and Lymphoma
  Recruiting · Memorial Sloan Kettering Cancer Center · Basking Ridge, New Jersey